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In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a 
drastic reduction of therapy duration. Until now, however, the mechanisms underlying PZA’s unique contribution to efficacy 
have remained controversial, and animal efficacy data vary across species. To understand how PZA kills bacterial populations 
present in critical lung lesion compartments, we first characterized a rabbit model of active TB, showing striking similarities 
in lesion types and fates to nonhuman primate models deemed the most appropriate surrogates of human TB. We next 
employed this model with lesion-centric molecular and bacteriology readouts to demonstrate that PZA exhibits potent 
activity against Mycobacterium tuberculosis residing in difficult-to-sterilize necrotic lesions. Our data also indicate that PZA 
is slow acting, suggesting that PZA administration beyond the first 2 mo may accelerate the cure. In conclusion, we provide 
a pharmacodynamic explanation for PZA’s treatment-shortening effect and deliver new tools to dissect the contribution of 
immune response versus drug at the lesion level.
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Introduction
With the advent of positron emission tomography/computed 
tomography imaging to monitor disease progression and thera-
peutic response in tuberculosis (TB) patients and nonhuman pri-
mates as well as rabbits, it has become apparent that within the 
same host different lesions can follow diverging trajectories in 
response to drug treatment (Via et al., 2012; Coleman et al., 2014; 
Malherbe et al., 2016). Clinical data accumulated over several de-
cades indicate that the presence and extent of cavitary disease is 
associated with treatment failure and relapse (Aber and Nunn, 
1978; Chang et al., 2004, 2006) or inferior outcome (Savic et al., 
2017), pointing to necrotic cavities as a key lesion type driving 
persistence of TB disease. Likewise, in preclinical efficacy stud-
ies that assess bacterial populations surviving drug treatment, 
the lesion compartments that fail to be sterilized at the end of 
therapy are mostly the caseous foci of closed nodules and cavities 
(Lenaerts et al., 2007; Lin et al., 2009; Hoff et al., 2011; Via et al., 
2015a). Thus, targeting lesions with a necrotic component ap-
pears critical to achieve treatment shortening and durable cure.
Pyrazinamide (PZA) was discovered in the 1950s and rapidly 
demonstrated clinical utility when added to TB drugs available 
at the time (Fox et al., 1999). Together with rifampicin, PZA con-
tributed to dramatic therapy shortening from 18 to 6 mo while 
maintaining low relapse rates (Hong Kong Chest Service/British 
Medical Research Council, 1982; Fox et al., 1999). As a result, PZA 
has been part of today’s first-line TB drug regimen since the 1980s 
and is also used to treat most multidrug-resistant cases. Based 
on numerous experiments in mice, this treatment-shortening 
property is attributed to PZA’s ability to eliminate persisting bac-
terial populations (McCune et al., 1956; McCune and Tompsett, 
1956) and achieve apparent sterilization in different mouse 
models (Lanoix et al., 2016 McCune et al., 1966a,b; Williams et 
al., 2012). Although early clinical trials failed to detect a benefit 
of prolonging PZA treatment beyond the first 2 mo, mouse effi-
cacy data suggest otherwise in the background of both first- and 
second-line regimens (McCune et al., 1966b; Ahmad et al., 2013; 
Lanoix et al., 2016).
Because PZA is largely recognized as a “sterilizing” drug 
(Mitchison, 1985, 2004b; Chigutsa et al., 2015) and necrotic le-
sions are most recalcitrant to therapy, it follows that PZA should 
be efficacious against bacterial populations that inhabit ne-
crotic niches. However, direct demonstration of PZA’s activity 
against these populations is lacking, and several recent findings 
indirectly support or contradict this hypothesis (Ahmad et al., 
2011; Irwin et al., 2015; Lanoix et al., 2015a; Prideaux et al., 2015; 
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Kempker et al., 2017; Sarathy et al., 2018). Interestingly, we pre-
viously observed that PZA contributes very little if anything in 
reducing bacterial burden in C3HeB/FeJ mouse necrotic lesions 
(Lanoix et al., 2015a; Irwin et al., 2016). To test the killing po-
tential and sterilizing activity of PZA in specific lesion types, 
we resorted to the rabbit model of active TB, known to exhibit 
a spectrum of human-like lesions (Manabe et al., 2003; Subbian 
et al., 2011; Via et al., 2012). First, the model was extensively 
characterized to assess the heterogeneity of individual lesion 
trajectory with regard to bacterial burden and immune-medi-
ated killing by using lesion-centric bacteriologic and molecular 
readouts that quantify both bacterial burden (measured as CFUs) 
and cumulative burden of viable and dead bacteria (measured 
as chromosome equivalents [CEQs]; Muñoz-Elías and McKinney, 
2005; Lin et al., 2014). In TB patients and nonhuman primates, 
the mechanisms that establish diverging granuloma fates involve 
complex interactions among host immune responses, inflamma-
tion, and bacterial processes (Sukumar et al., 2014; Marakalala et 
al., 2016; Cadena et al., 2017). Indeed, lesion-centric analyses in 
rabbits with active TB revealed that, although some lesions seem 
to restrict bacterial growth and achieve local sterilization, others 
display increasing bacterial burden as disease progresses. These 
observations indicated that immunopathology and lesion hetero-
geneity compare favorably between rabbits and nonhuman pri-
mates or TB patients (Coleman et al., 2014; Lenaerts et al., 2015; 
Martin et al., 2017). We next built on these findings to measure 
PZA-mediated killing at the lesion level. Our results validate the 
rabbit model as a tool to evaluate TB drug efficacy. They also 
provide an incentive to revisit the use of PZA beyond the 2-mo 
intensive phase of therapy and to discover more-potent PZA ana-
logues to accelerate the cure and reduce relapses of a disease that 
recently became the single leading infectious cause of death in 
adults, surpassing HIV (World Health Organization, 2017).
Results and discussion
Heterogeneity of lesion trajectory in the rabbit model
In TB patients and nonhuman primates, pulmonary lesions are 
characterized by diverging trajectories both in terms of bacterial 
load and immunopathology (Coleman et al., 2014; Martin et al., 
2017). To compare the rabbit model of active TB to human disease 
and nonhuman primate models and assess its utility as a tool to 
measure drug efficacy in different lesion types, we performed le-
sion-centric analyses over the course of 20 wk of chronic disease. 
This initial analysis included 40 rabbits and 1,063 lesions. Indi-
vidual lesions were subjected to bacterial burden quantification 
(CFU) and histopathology profiling at various time points from 4 
to 20 wk postinfection. In addition, cumulative burden was mea-
sured by real-time quantitative PCR (qRT-PCR) to capture total 
viable and dead bacilli as CEQs and infer the efficiency of killing 
by the immune response in each lesion.
To track lesion burden over time in drug-naive animals, we 
plotted the CFU in cellular and necrotic lesions (where “necrotic 
lesions” encompass caseous granulomas and cavities) over the 
entire 20-wk course of infection (Fig. 1 A). At 4 wk postinfection, 
all but one of the granulomas were cellular with a relatively uni-
form bacterial load, slightly >104 CFU per lesion. From then on, 
lesion burden started to diverge and reached the widest range at 
20 wk postinfection, from fully sterile (no recoverable CFU on 
agar with a limit of detection [LOD] of 5 CFU per lesion) to 107 
bacilli per lesion. In rabbits with established TB disease (12 –20 
wk postinfection), we found that the bacillary burden per lesion 
was highly variable within individual animals (Fig. 1 B). Across 
time points, necrotic granulomas and cavities harbored higher 
bacterial burden than cellular lesions. We did not observe any 
lung lobe bias in the distribution of lesions and bacterial bur-
den (not shown). Sterile lesions started to appear around 8–10 
wk, and the bulk of lesion sterilization was achieved between 12 
and 15 wk postinfection (Fig. 1 C). At 15 and 20 wk postinfection, 
the proportion of sterile lesions was significantly higher in the 
cellular granuloma category (Fig. 1 C), with 49 and 35% in the 
cellular category and 42 and 13% in the necrotic category, respec-
tively. Similar proportions have been observed in drug-naive 
nonhuman primates (Lin et al., 2014). As observed for the range 
of CFUs per lesion, the range of lesion mass within individual 
rabbits was tight early on and increased as disease progressed 
(Fig. S1 A). A correlation trend was observed between bacterial 
load and lesion weight (r2 = 0.49 and 0.38 for cellular and necrotic 
lesions, respectively; Fig. S1 B). We also quantified the burden of 
seemingly uninvolved lung (Fig. S1 C, lung parenchyma with var-
ious degrees of cellular infiltration by lymphocytes, histiocytes, 
and polymorphonuclear cells, not organized as circumscribed 
lesions). We found a substantial bacterial burden in uninvolved 
lung, the median of which was approximately two orders of mag-
nitude lower than in lesions up to 12 wk postinfection (Fig. S1 
D). This low burden could originate from microlesions not de-
tected upon macroscopic examination and dissection or from 
immune-privileged sites where small numbers of Mycobacte-
rium tuberculosis (Mtb) bacilli are “tolerated” by the immune 
system. At 4 wk, all uninvolved lung samples were CFU-positive 
(median 2.2 log CFU per lesion), similar to cellular lesions (me-
dian 4.2 log CFU per lesion). As disease progressed, uninvolved 
lung followed the same sterilization pattern as cellular lesions 
(Fig. S1 D), compatible with the notion that the burden present 
in uninvolved lung could originate from small cellular lesions, 
which the immune system either eradicates or allows to develop 
as mature lesions. This doesn’t exclude the possibility that unin-
volved lung also contains immune-privileged sites that harbor 
pathogen reservoirs. One could speculate that “dominant” lesions 
attract the bulk of immune cells, causing spatial and temporal 
relief of immune pressure in neighboring areas.
To assess the degree of bacterial killing in individual lesions, 
we took advantage of the finding that genomes (CEQs) from non-
viable Mtb largely persist in tissues (Muñoz-Elías et al., 2005; Lin 
et al., 2014). CEQs reflect the cumulative bacterial burden, and 
the CEQ/CFU ratio is an indirect measure of bacterial killing over 
time. Similar to CFU, the cumulative burden per lesion fell within 
a tight range at 4 wk, after which the range widened dramatically 
to peak between 15 and 20 wk postinfection (Fig. 1 D), with a high 
within-animal variability in CEQ/lesion after 8–10 wk (Fig. S1 E).
Compiling the CEQ/CFU ratios per lesion over time revealed 
virtually no kill (median CEQ/CFU = 1) at 4 wk postinfection. 
From then on, lesion trajectories started to diverge both in cellu-
lar and necrotic lesion categories (Fig. 1 E). The range of CEQ/CFU 
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ratios markedly increased between 12 and 15 wk, consistent with 
the concomitant burst in sterile lesions (Fig. 1 C). As CFUs in-
creased, the spread of CEQs decreased, suggesting failed immu-
nity in lesions with high bacterial burden (Fig. S1 F). Accordingly, 
we found an inverse correlation between the CEQ/CFU ratio and 
the CFU content of individual lesions, from completely sterile 
with high CEQ/CFU to very high bacterial burden with poor kill-
ing (Fig. S1 G). Separate plots of CEQ versus CFU at each time 
point showed that departure from the CFU-CEQ line of equality 
increases over time, until week 16 when immune mediated kill-
ing appears to peak, and that failure of the immune response in 
a subset of the lesions was best revealed from week 16 to week 
20, where high-CFU lesions (>106 CFU per lesion) appeared with 
little to no killing (Fig. S1 H). Altogether, these observations 
demonstrated diverging lesion trajectories reminiscent of the 
nonhuman primate model of active TB (Lin et al., 2014; Via et al., 
2015a), thus confirming the utility of the rabbit model to study 
the lesion-centric effect of TB drugs.
Histopathologic analyses revealed mostly cellular granulomas 
up to 4 wk (1–4 mm in diameter), at which point the pathology di-
verged, leading to the presence of cellular, early-necrotizing and 
fully necrotic granulomas of various sizes (ranging from 1 to 10 
mm) from 10 wk onward, as reflected by the increase in the range 
of lesion mass within individual rabbits (Fig. S1 C). Clusters of 
coalescing granulomas and occasional cavities were observed 
after 8 wk, and lesion size exceeded 10 mm in rare occasions (up 
to 25 mm). A minority of rabbits presented with mild pathology 
and very few organized lesions. The cellularity of necrotic foci 
in granulomas and cavities was highly variable and mostly com-
posed of neutrophils (Figs. 2 and S2). Acid-fast staining revealed 
a higher abundance of bacteria in caseous foci with higher neu-
trophilic infiltration, aligned with previous observations that 
neutrophils appear to create a nutrient-rich environment and 
that Mtb exploits neutrophilic inflammation to preferentially 
replicate at sites of tissue damage that promote transmission 
(Mishra et al., 2017; Philips, 2017; Figs. 2 and S2). We measured 
the pH of the caseous foci of ∼20 lesions and found a range of 
values from 6.1 to 8.0 (median, 6.7), reflecting an additional di-
mension of rabbit lesion heterogeneity (Table S1).
To assess genetic heterogeneity of Mtb at the lesion level, we 
subjected 23 strains isolated from 23 lesions (cellular and necrotic 
from four rabbits infected for 20 wk) to whole-genome sequenc-
Figure 1. Lesion-centric bacterial burden and 
cumulative burden in drug-naive rabbits with 
active TB. (A) Evolution of bacterial load per lesion 
from 4 to 20 wk postinfection. (B) Range of CFU/
lesion within individual rabbits from 4 to 20 wk post-
infection. (C) Proportion of cellular (empty bars) and 
necrotic (gray bars) lesions as disease progresses 
from 4 to 20 wk postinfection; actual numbers of 
sterile versus total lesions are indicated on top of 
each bar. (D) Evolution of the cumulative bacterial 
burden per lesion from 4 to 20 wk postinfection. (E) 
CEQ/CFU ratios within lesions, an indirect measure 
of the extent of immune-mediated killing, over the 
20-wk disease course. Data from three independent 
experiments were combined to generate the plots. 
Asterisks indicate statistical significance by using the 
Mann-Whitney U test in A, B, D, and E and Fisher’s 
exact test in C. *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001.
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ing. Five strains (22%) displayed one to three single nucleotide 
polymorphisms (SNPs), and different polymorphisms were found 
in different lesions within the same animal (Table S2), indicat-
ing localized genetic variation. In total, we detected nine SNPs in 
3,220 lesion days (23 lesions from rabbits infected for 140 d) or one 
SNP per 358 lesion days. In comparison, Ford et al. (2011) detected 
four SNPs in 1,541 nonhuman primate lesion days, or one SNP in 
385 lesion days. Thus, bacterial variability is similar in both mod-
els and supports the concept of lesion specific evolution of Mtb.
In summary, the fate of lesions diverged gradually from 4 wk 
postinfection onward, within the same host. Lesional hetero-
geneity arose, in part, through differential killing of bacteria 
after the onset of adaptive immunity, leading to a broad range 
of bacterial burden within and across animals. Many features 
of the rabbit model were reminiscent of observations made in 
nonhuman primates with active TB (Via et al., 2013; Lin et al., 
2014; Martin et al., 2017): (1) individual lesions followed diverg-
ing trajectories; (2) a spectrum of pathology with occasional 
cavitation was observed across animals; (3) the average bacte-
rial burden per lesion at 4 wk was homogeneous and around 104 
CFU, followed by a gradual broadening of the range of burden 
and immune killing as reflected by the “funnel" shape of CFU and 
CEQ kinetics at the lesion level; (4) the average bacterial burden 
per lesion decreased from 8 wk onward, and immune-mediated 
killing peaked between 12 and 16 wk; and (5) within the same 
host, different lesions harbored Mtb strains with different SNPs, 
supporting the concept of lesion-specific evolution of bacteria. 
Importantly, histology findings recapitulated observations made 
in human biopsies and resected tissues: Mtb bacilli were sparse 
in most caseous foci and, when present, were mostly associated 
with karyorrhectic neutrophils. This is consistent with neutro-
phils being increasingly recognized as providing a permissive 
site for Mtb replication (Diedrich et al., 2016; Mishra et al., 2017) 
(Lowe et al., 2012), and with the finding that Mtb is largely found 
in neutrophils in sputum, bronchoalveolar lavage, and cavity 
contents (Eum et al., 2010). The rabbit model thus reproduced 
several typical primate features and appeared as a suitable tool 
to evaluate drug activity in individual lung lesions.
PZA markedly reduces bacterial burden in necrotic lesions
PZA and rifampin are together responsible for almost all of 
the treatment shortening and sterilizing activity of the stan-
dard treatment of pulmonary TB (East African/British Medical 
Research Councils, 1972; Mitchison, 2004a), a finding that gen-
erally leads to the belief that PZA must sterilize necrotic lesions 
considered to harbor “persister” bacilli (Mitchison, 1985, 2010). 
Figure 2. Histopathological heterogeneity in rabbits with active TB and 
association of Mtb bacilli with neutrophils. (A) H&E staining of a cluster 
of small necrotizing granulomas with extensive infiltration of polymorphonu-
clear neutrophils in the nascent necrotic core, surrounded by a rim of epithe-
lioid macrophages and lymphocyte-dominated inflammation at the periphery 
(16 wk postinfection). (B) Large necrotic granuloma with classical eosinophilic 
caseum in the necrotic core and low cellularity consisting of few degenerate 
neutrophils (16 wk postinfection). Foamy macrophages are located adjacent to 
the caseous necrosis. Panels C and E and panels D and F show a magnification 
of the regions highlighted in A and B, respectively. (C) Active neutrophil influx 
in the early necrotic core. (D) Caseum with limited cellular infiltrate. E and F 
are Ziehl-Neelsen stains of the regions shown in C and D. Black arrows in E 
point to Mtb bacilli found in high numbers in areas with high neutrophilic infil-
tration. (F) Lack of acid-fast bacilli within the paucicellular caseum. (G) H&E 
staining of a large cavity at 8 wk postinfection shows prior expulsion of central 
necrotic material and inflammatory destruction and erosion into neighboring 
pulmonary vein. (H) Magnification of the neutrophil-rich region highlighted 
in G showing the interface between low- and high-cellularity areas with high 
density of neutrophils. Black arrows point to an area of fibrosis at the cavity 
margin. (I and J) Ziehl-Neelsen stains of the regions shown in G and H, with 
high numbers of bacilli found in the vicinity of neutrophils. Scale bars: 500 µm.
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However, efficacy studies in various animal models have deliv-
ered conflicted data. In published studies using guinea pig and 
mouse models, the effect of PZA on bacterial burden was assessed 
in whole lungs, and associations between sterilization and the 
presence of necrotic lesions were explored. This approach has 
delivered mixed conclusions as to the activity of PZA in necrotic/
caseous lesions (Ahmad et al., 2011; Lanoix et al., 2015a; Irwin 
et al., 2016). Having shown key similarities of the rabbit model 
with human and nonhuman primate disease, we leveraged the 
model to directly quantify the lesion-centric activity of PZA and 
shed light on the pharmacodynamic basis of its sterilizing activ-
ity. CFUs and CEQs were measured in dissected lesions of PZA-
treated and control rabbits after 5 and 10 wk of daily therapy at 
175 mg/kg, starting 10 wk postinfection. To ensure on-target PZA 
exposure at steady-state, three rabbits were randomly assigned 
to a pharmacokinetic (PK) therapeutic drug monitoring substudy 
after 3 wk of treatment. The average area under the concentra-
tion-time curve (AUC) of PZA and pyrazinoic acid (POA; active 
metabolite of PZA) closely matched the simulated AUC based on 
PK in uninfected rabbits (Tables S3 and S4). Using matrix-as-
sisted laser desorption ionization (MAL DI) mass spectrometry 
imaging (MSI) and laser-capture microdissection (LCM) cou-
pled to mass spectrometry, we also confirmed previous clinical 
observations by our group (Prideaux et al., 2015) and showed 
that in rabbits PZA distributes favorably from plasma into lung 
lesions (Fig. 3 A) and diffuses rapidly into necrotic foci to reach 
concentrations similar to those measured in plasma within 2 h 
postdose (Fig. 3 B). Thus, distribution to the site of infection and 
diffusion into avascular caseum does not constitute a barrier 
to PZA efficacy.
At 175 mg/kg daily, PZA significantly reduced bacterial bur-
den in cellular and necrotic lesions after 5 and 10 wk of treat-
ment (Fig.  4  A). Likewise, CFUs normalized to lesion weight 
significantly decreased in all treated groups (Fig.  4  B). A sig-
nificant PZA-mediated reduction of average lesion mass was 
observed only in the necrotic lesion category at the late time 
point (Fig.  4  C). This result indicates that PZA-mediated CFU 
reduction precedes a decrease of the average weight of necrotic 
lesions. PZA treatment also caused a significant increase in the 
proportion of sterile lesions, cellular and necrotic, after 5 and 
10 wk of treatment, in addition to immune-mediated steriliza-
tion (Fig. 4 D), which peaks between 12 and 15 wk postinfection 
(Fig. 1 C). Thus, all observations were consistent with PZA being 
active in all lesion types and having at least as great an effect in 
necrotic granulomas as in cellular granulomas.
To distinguish the contribution of immune- and drug-medi-
ated killing within individual lesions, we compared the CEQ/CFU 
ratios in treated and untreated rabbits as a function of lesion type 
(Fig. 5). Values of log CEQ/CFU per lesion were assigned to bins, 
and the proportion of lesions falling into each bin was plotted for 
treated and untreated lesions, categorized as cellular or necrotic. 
The same analysis was performed for uninvolved lung. This anal-
ysis revealed that in cellular lesions the contribution of PZA was 
not significant at 10 wk (Fig. 5 A) and that PZA most significantly 
added to immune-mediated killing in necrotic lesions after 10 wk 
of treatment (Fig. 5 B). By the time PZA treatment was initiated, 
most uninvolved lung samples had become sterile; however, PZA 
showed a clear effect at the late time point in uninvolved lung 
areas that were still culture positive (Fig. 5 C).
Thus, the PZA-mediated effect on CFUs, bacterial kill as re-
flected by CEQ/CFU, complete lesion sterilization, and lesion 
weight appeared most pronounced in necrotic lesions after 10 
wk of treatment. This finding provides a pharmacodynamic 
explanation for the treatment-shortening property of PZA: the 
Figure 3. Penetration of PZA in cellular and necrotic lesions. (A) Two left panels: ion maps of PZA [M+2H]+ in rabbit lung tissue sections that encompass 
cellular and necrotic granulomas. The PZA [M+2H]+ signal intensity scale is linear and shown to the left. Middle panels: H&E stains of the corresponding adja-
cent sections. N, necrotic core or caseum; C, cellular rim or fully cellular granuloma; L, uninvolved lung. Right panels: optical images of the sections used for 
MAL DI-MSI. The necrotic core of caseous granulomas is highlighted by the black contour lines in the ion maps (left) and white contour lines in the H&E stained 
section and optical image. Scale bars: 5 mm. (B) Quantitation of PZA in the necrotic or caseous core, cellular rim, and surrounding lung tissue of four lesions 
collected in two rabbits, obtained by LCM coupled to HPLC/tandem mass spectrometry. Each value was normalized to plasma concentrations measured at 
the time of tissue sampling.
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drug appears to exert its effect by targeting bacilli present in the 
difficult-to-sterilize caseum of necrotic lesions. Consistent with 
PZA’s activity in necrotic lesions, previous work by our group has 
shown that it is bactericidal against Mtb in an ex vivo caseum 
assay (Sarathy et al., 2018). Of note, the PZA concentration re-
quired to achieve a 1-log kill in this assay is around 20–40 µg/ml, 
levels that are reached only for a short portion of the dosing in-
terval both in rabbits and in patients (Wilkins et al., 2006; Via et 
al., 2015b). The pH of ex vivo caseum under the assay conditions 
was around 7.5 and thus at the higher end of the pH spectrum we 
measured for rabbit caseum in the current study. Because PZA 
is more potent at a lower pH (McDermott and Tompsett, 1954; 
Salfinger and Heifets, 1988; Zhang et al., 2002), the ex vivo bac-
tericidal assay may not have revealed the full potential of PZA in 
caseous environments. In the present study, the PZA dose of 175 
mg/kg administered 7 d/wk reproduces human exposure at the 
lower end of the AUC spectrum observed in patients receiving the 
standard PZA dose of 1,500 mg daily (Wilkins et al., 2006). There-
fore, we may have slightly underestimated the activity of PZA.
The marked efficacy of PZA in necrotic lesions in the rabbit 
model corroborates a comparative efficacy study in guinea pigs, 
which develop necrotic lesions and in which PZA was more active 
than in BALB/c mice, which do not present necrotic granulomas 
(Ahmad et al., 2011). In contrast, C3HeB/FeJ mice with large ne-
crotic granulomas responded poorly to PZA treatment compared 
with C3HeB/FeJ mice that harbored mostly cellular lesions (Irwin 
et al., 2016). These discrepancies were attributed to the relatively 
high pH of C3HeB/FeJ mouse caseum (Lanoix et al., 2015a). The 
range of caseum pH measured in this study (6.1–8.0) is in line with 
the human caseum pH range of 5.5–8.0 (Koller and Leuthardt, 
1934; Dahl, 1950; Weiss et al., 1954; Kempker et al., 2017). Thus, 
in rabbits and TB patients, different lesions present pH condi-
tions that are more or less favorable to PZA’s activity, which may 
contribute to the observed interlesion variability in treatment 
response. It has also been suggested that localized areas of acute 
inflammation are associated with low O2 tension, accumulation of 
CO2 and lactic acid, and secretion of succinate by the tuberculous 
bacilli, leading to pH values as low as 5.0–5.5 in selected microen-
vironments (von Ardenne and Krüger, 1979; Watanabe et al., 2011).
There are a few limitations in this study. First, an apparent drop 
in average CEQs per lesion over time in cellular granulomas indi-
rectly points to a potential decay of CEQs, possibly due to partial 
degradation of Mtb DNA by activated immune cells (Fig. S3, A and 
B). However, this apparent decrease could also be due to the emer-
gence of new cellular lesions as disease progresses, with truly low 
cumulative burden. In addition, because DNA decay is likely to af-
fect both untreated and PZA-treated lesion sets to the same extent, 
evaluation of PZA efficacy should remain largely unaffected. Sec-
ond, the necrotic lesion category includes closed caseous nodules 
and open cavities, which cannot be distinguished at the time of 
dissection because large closed nodules and nascent cavities that 
have just connected to an airway cannot be differentiated upon 
macroscopic examination. Based on follow-up histological stud-
ies, we estimate that <5–10% of necrotic lesions are open cavities.
If PZA sterilizes necrotic lesions, why aren’t TB patients cured 
faster? First, PZA suffers from rather modest potency, with a min-
imum inhibitory concentration ranging from 12.5 to >100 µg/ml 
(∼1 mM), depending on pH and other environmental conditions 
(Zhang et al., 1999, 2002; Sarathy et al., 2018). Accordingly, PZA’s 
sterilizing effect in necrotic lesions was slow: in rabbits, the drug 
exerted most of its activity during the second half of the treat-
ment period, after 5–10 wk (Fig. 5 B). Clinically, PZA is excluded 
from the continuation treatment phase (months 3–6) in patients 
with drug-susceptible TB based on (1) numerous large clinical tri-
als conducted by the British Medical Research Council from which 
it was concluded that TB patients may not benefit from prolonged 
PZA therapy beyond 2 mo (Fox et al., 1999; Mitchison, 2004a) and 
(2) PZA-mediated hepatotoxicity (Centers for Disease Control 
and Prevention; American Thoracic Society, 2003). However, a 
trend toward lower relapse rates has been seen in trials in which 
Figure 4. Antimycobacterial activity of PZA in cellular and necrotic lesions. (A) Effect of PZA on the bacterial burden of individual lesions in rabbits with 
active TB, after 5 and 10 wk of daily treatment. C, untreated controls. Median and 95% CI are shown (both median and 95% CI are at 10° for the PZA control 
groups in the cellular lesion category). Asterisks indicate statistical significance BY using the two-tailed Mann-Whitney U test. (B) Bacterial burden normalized 
to tissue weight in uninvolved lung tissue (“normal”) and in cellular and necrotic lesions. Because all CFU data are plotted on a log scale, all CFU values are 
converted to CFU + 1 order to include “zero CFU” data points. This method is not appropriate when normalizing to tissue weight because a difference of 1 
would substantially skew the CFU-per-milligram dataset for the zero CFU subset. To visualize zero CFU data points, these were assigned an arbitrary low value 
of 10−4, then normalized to tissue weight. The median and 95% CI were calculated by using actual zero values. Medians that do not appear on the graph have 
a value of zero. (C) Effect of PZA treatment on lesion weight. Asterisks indicate statistical significance by using the Mann-Whitney U test. (D) Effect of PZA on 
the proportion of sterile lesions after 5 and 10 wk of treatment (actual numbers of sterile versus total lesions are indicated on top of each bar). Data from two 
independent experiments were combined to generate the plots. Statistically significant differences between two proportions were detected by using Fisher’s 
exact test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (43 < n < 98 per treatment group).
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PZA was administered beyond 2 mo, although statistical signif-
icance was not reached (Tuberculosis Service/British Medical 
Research Council, 1981; Mitchison, 2004a). In early bactericidal 
activity trials, PZA consistently shows modest activity during the 
first 2 d, after which the decrease in sputum counts accelerates, 
unlike other first-line drugs (Jindani et al., 2003). Likewise, a 
thorough analysis of serial sputum counts in patients receiving 
various combinations of front-line agents for 28 d revealed that 
the contribution of PZA was most pronounced during the second 
half of the study, from day 14 to 28 (Brindle et al., 2001). In ad-
dition, preclinical models have revealed a benefit of continuing 
PZA treatment beyond 2 mo, in the background of both first- and 
second-line regimens (Tasneen et al., 2008; Ahmad et al., 2013; 
Lanoix et al., 2015b). All these observations converge toward 
a rather slow “onset” of PZA activity. Together, our results may 
lead to rethinking the current treatment paradigm according to 
which PZA is given for the first 2 mo only. To avoid prolonged use 
of PZA beyond 2 mo given its hepatotoxicity, one could consider 
including PZA only after other agents have reduced the bacterial 
burden, leaving mostly persisters behind. Although clinical trials 
conducted by the British Medical Research Council in the 1960s to 
1970s concluded no benefit of PZA beyond 2 mo, the utility of a late 
introduction of PZA has not been clinically tested, particularly 
in the context of today’s more refined readouts and biomarkers. 
Elucidation of the pharmacological mechanism underlying PZA’s 
unique clinical efficacy, together with the recent characterization 
of its antibacterial mechanism of action (Dillon et al., 2014; Gopal 
et al., 2016, 2017), provides the basis for the rational development 
of next-generation, more-potent PZA analogues.
Materials and methods
Infection, tissue dissection, and sample processing for 
bacterial burden
All animal studies were performed in Biosafety Level 3 facilities 
and approved by the Institutional Animal Care and Use Committee 
of the New Jersey Medical School, Rutgers University, Newark, NJ. 
Female New Zealand White rabbits (Millbrook Farm), weighing 
2.2–2.6 kg, were maintained under specific pathogen-free condi-
tions and fed water and chow ad libitum. The rabbits were infected 
with Mtb HN878 in rounds of six animals by using a nose-only 
aerosol exposure system as described, leading to the development 
of chronic active TB with cellular and necrotic granulomas in all 
animals, as well as occasional cavities (Subbian et al., 2011). 3 h 
postinfection, one rabbit from each round of infection was eu-
thanized to determine the bacterial load implanted in the lungs, 
with a target of 1,000–3,000 CFU per rabbit. To characterize Mtb 
growth kinetics and pathology, untreated rabbits were necrop-
sied and analyzed at the following time points: three, four, four, 
eight, seven, eight, and six rabbits at 4, 8, 10, 12, 15, 16, and 20 wk 
postinoculation, respectively. At each time point, rabbits were se-
dated with ketamine and xylazine, were euthanized by Euthasol, 
and underwent necropsy. The right and left lungs were removed 
and weighed. Individual lesions and uninvolved (not contain-
ing macroscopically visible lesions) lung tissue were dissected, 
weighed, and recorded; lesions were categorized as fully cellular 
(recorded and labeled as “cellular”) or necrotic (made of a cellular 
rim surrounding the necrotic or caseous core). Necrotic lesions 
are easily distinguishable from cellular granulomas due to (1) the 
presence of a white-to-yellow core visible upon macroscopic ex-
amination because granulomas are translucent and (2) the fact 
that cellular granulomas are more firm to the touch than necrotic 
lesions. When the distinction was subject to doubt, a fine needle 
was used to pierce through the center of the lesion, followed by 
gentle pressing leading to oozing of necrotic material in the case 
of necrotic lesions. The necrotic lesion category includes closed 
necrotic nodules and cavities, because it is not possible—upon 
macroscopic examination at the time of dissection—to reliably 
distinguish between a large closed nodule and a nascent cavity that 
has just connected to an airway. Special care was taken to remove 
the uninvolved lung tissue surrounding each lesion. An average 
of 10 necrotic lesions, 8 cellular lesions, and 6 uninvolved lung 
Figure 5. Effect of PZA on the extent of bacterial killing or CEQ/CFU 
ratio at the lesion level in cellular lesions (A), necrotic lesions (B), and 
uninvolved lung (C). To visualize the effect of PZA-mediated bacterial killing 
in addition to killing by the immune system, the data are presented as log 
CEQ/CFU ratio assigned to bins in 0.5-log increments in untreated rabbits 
(gray bars, immune killing only) and drug treated rabbits (blue bars, combined 
immune and PZA-mediated kill). Statistical analyses were performed by using 
nonlog normalized values. Data points where both CFU and CEQ values were 
below the LOD were excluded from this analysis. Data from two independent 
experiments were combined to generate the plots. Asterisks indicate statis-
tically significant differences between the PZA treated and untreated groups 
by using the two-tailed Mann-Whitney U test (used to compare the CEQ/CFU 
ratios before log transformation and before binning). *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001.
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samples were collected from each rabbit. Tissue samples <0.05 g 
and >0.05 g were homogenized in either 200 µl or 500 µl PBS 
respectively. Serial dilutions of the tissue homogenates were pre-
pared in PBS supplemented with 0.025% Tween and plated on 
Middlebrook 7H11 agar. The plates were incubated at 37°C for at 
least 21 d before determining final CFU counts. The lower LOD of 
CFU for each lesion is 3–5 depending on the total homogenization 
volume and the final volume and dilution plated (Dataset S1).
Treatment
Starting 10 wk postinfection, 14 rabbits received 175 mg/kg 
PZA 7 d/wk for either 5 wk (7 rabbits) or 10 wk (7 rabbits). At 
15 and 20 wk postinfection or after 5 and 10 wk of PZA treat-
ment, rabbits were sedated with ketamine and xylazine, were 
euthanized by Euthasol, and underwent necropsy. Lesion and 
tissue samples were collected and processed as described above. 
After ∼3 and 7 wk of daily PZA treatment, blood was collected 
from the central ear artery of each rabbit predose and at 0.5, 1, 
2, 4, 6, and 24 h after oral gavage to assess exposure in infected 
rabbits at steady-state and compare with the average exposure 
achieved in TB patients receiving a standard dose. Blood sam-
ples were centrifuged at 4,000 rpm for 5 min, and the super-
natants (plasma) were transferred and stored at −80°C until 
analyzed by HPLC coupled to tandem mass spectrometry as de-
scribed in (Via et al., 2015b).
Human-equivalent PZA dose projection
PZA (Sigma Aldrich) was formulated in 40% sucrose and dosed 
at 175 mg/kg. The following rationale was followed in order to 
select this dose. In rabbits, the conversion of PZA to POA by the 
liver is significantly higher than in humans (Via et al., 2015b). 
Because POA is almost as potent as PZA against Mtb in vitro 
(Gopal et al., 2016), one could consider two different approaches 
in selecting a human-equivalent dose: (1) to match the sum of 
the AUCs of PZA and POA (AUCPZA and AUCPOA) achieved in TB 
patients receiving a standard dose of 1,500 mg or ∼450–500 
mg/h/L, corresponding to a rabbit dose of 100 mg/kg, or (2) to 
match AUCPZA only or 350–400 mg/h/L, corresponding to a rab-
bit dose of 275–300 mg/kg. The former approach assumes that 
circulating POA (as opposed to POA generated inside Mtb bacilli) 
is equipotent to PZA, which we found not to be the case in a sepa-
rate study (Lanoix et al., 2016). Thus, we opted for a compromise 
and selected a dose of 175 mg/kg (Tables S3 and S4), leading to 
peak plasma concentrations (Cmax) of 50–75 mg/L (mean, 69.2 
mg/L) and an AUC of 230–240 mg/h/L at steady-state, which 
correspond to the PZA Cmax and AUC of TB patients at the higher 
(Cmax) and lower (AUC) end of the exposure spectrum, respec-
tively (Wilkins et al., 2006).
MAL DI-MSI and LCM
Two rabbits were infected as described above, and disease was 
allowed to progress for 11 wk, at which point the rabbits received 
a single dose of PZA at 300 mg/kg (a higher dose was used than 
in efficacy studies to overcome the relatively poor ionization of 
PZA by MAL DI-MSI), after which lesions and the surrounding 
lung tissue were collected 2 h postdose and stored as described 
previously (Zimmerman et al., 2017). 12-µm-thick tissue sections 
were prepared from γ-irradiated biopsies for MAL DI-MSI and 
analyzed by using a MAL DI LTQ Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific) as previously described (Prideaux et 
al., 2015). Serial 25- and 12-µm-thick sections were prepared for 
LCM coupled to high-pressure liquid chromatography and tan-
dem mass spectrometry quantitative analysis, and H&E staining 
respectively. Microdissection and quantification of caseum, cel-
lular lesion, and uninvolved lung were performed as previously 
described (Zimmerman et al., 2017).
Histology
Five pieces of lung tissue (one per lobe) from each rabbit were 
fixed in 10% formalin (Thermo Fisher Scientific) and sent to IDE 
XX BioResearch. These sections were paraffin-embedded and 
used for standard 5-µm sectioning. Sections were then stained 
with H&E for cellular composition and with Ziehl-Neelsen ac-
id-fast staining to visualize Mtb bacilli. Images of the stains 
were captured and analyzed by using Pannoramic Viewer and 
Pannoramic Desk (Caliper Life Science).
CEQ determination in lung and lesion tissues
Genomic DNA was extracted from homogenized tissue samples 
after Qiagen DNA extraction protocol by using the QIAamp 96 
DNA Qiagen Kit (Slana et al., 2010). Samples were thawed, and 
100 µl was transferred to a 96-well plate (S-Block; Qiagen) con-
taining 180 µl stool lysis ASL buffer (Qiagen), 20 µl proteinase 
K (Qiagen), 1  µl reagent DX (Qiagen), and 250  µl of 0.1-mm 
zirconia-silica beads (MP Biomedicals) in each well. Tissues 
were digested for at least 1 h at 56°C, then inactivated for 1 h at 
80°C. Samples were homogenized by two pulses of 1 min each 
at 1,750 rpm on the Geno/Grinder 2010 (Spex Sample prepP), 
with a 5-min break between pulses. The plate was centrifuged 
at 200 g to remove foam and precipitate beads, then loaded in a 
QIAcube HT (Qiagen). Samples were mixed with 600 µl of 50% 
buffer AL (Qiagen) and 50% ethanol (Fisher Scientific). 600 µl 
of supernatant from each well was transferred onto a 96-well 
plate silica column (Qiagen) and drawn through by using a 
vacuum pump. DNA samples were cleaned with three consecu-
tive wash steps: 600 µl buffer AW1 (Qiagen), 600 µl AW2 (Qia-
gen), and 600 µl ethanol. DNA was then eluted with a total of 
100  µl buffer AE (Qiagen). Mtb CEQ was quantified by using 
the previously described protocol (Muñoz-Elías et al., 2005) 
with sigF primer-probe combination (Integrated DNA Technol-
ogies) adapted from Lin et al. (2014). CEQ quantification was 
achieved by building standard curves by using serial dilutions 
of whole Mtb genome prepared from broth culture. qRT-PCR 
reactions were performed in duplicate at dilution 1×, 3×, and 9× 
(for a total of six quantitative PCR [qPCR] measurements per 
sample) on either the Mx3005P (Stratagene) or Step One Plus 
(Applied Biosystems) by using TaqMan Universal Master Mix II 
(Life Technologies).
Validation of DNA extraction and qRT-PCR to assess CEQs 
in lung lesions
Bacteria were grown in 7H9 media with 10% ADC and 0.05% 
Tween 80. Serial dilutions of this culture were plated on 7H11 for 
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CFU-per-milliliter enumeration (Fig. S3 C). To assess the total 
number of culturable, nonculturable, and dead cells in the same 
culture, all of which should be captured in qRT-PCR as CEQs, 
individual cells were counted with a hemocytometer (Neubauer) 
on a microscope (Leica DM6000 B, 400× magnification). The 
number of bacteria present in aggregates was estimated visu-
ally (Fig. S3 D). Serial dilutions were prepared, and 100  µl of 
each dilution was spiked in 100 µl of rabbit lung homogenate, 
then used as template for qRT-PCR as described above. To as-
sess the variability of the qPCR procedure, each extract was di-
luted 1×, 3×, and 9× in duplicate to estimate the variability of the 
qPCR procedure and readout. The results are shown in Fig. S3 
E. Next, we calculated the CEQ/total bacterial particles ratio in 
order to estimate the combined efficiency of DNA extraction and 
accuracy of qPCR analysis (Fig. S3 F). Under most conditions, 
the CEQ readouts ranged between 50 and 200% of the total es-
timated number of bacteria, thus a plus or minus twofold error. 
Precision was slightly lower at very low and very high bacte-
rial loads, as expected. The LOD was ∼50 total bacterial cells, 
from which we inferred a limit of quantitation between 50 and 
100 chromosomes.
Whole-genome sequencing
After plating of rabbit lung tissue and lesion homogenates, 
mycobacterial genomic DNA was extracted as described previ-
ously (Blumenthal et al., 2010). Briefly, colonies were purified 
on 7H11 agar medium and used to inoculate 7H9 liquid cultures. 
Mtb HN878 genomic DNA was extracted as described (van 
Soolingen et al., 1991). DNA samples were prepared for sequenc-
ing by using the standard paired-end whole-genome DNA sample 
preparation kit from Illumina (Illumina Inc.). Samples were se-
quenced on an Illumina HiSeq 2500 next-generation sequencer, 
operated in paired-end mode, with a read length of 120 bp. The 
mean depth of coverage (reads per site) was 202.7× per genome 
(range, 90–1,445). Base-calling was performed by using Casava 
software, v1.8. The reads were aligned to Mtb HN878 (Genbank 
accession no. NZ_CM001043.1) as a reference genome by using 
the Burrows-Wheeler Alignment Tool (Li and Durbin, 2009). 
Indels were identified by building local contigs spanning sites 
with low coverage or heterogeneity of nucleotides, as described 
previously (Ioerger et al., 2010). Polymorphisms were identified 
by comparing (aligning) each genome to the sequence of HN878 
and tabulating SNPs and insertions/deletions, excluding those 
in heterogeneous sites (majority nucleotide <70%) and sites in 
low-coverage (<10×) or repetitive regions. The laboratory stock 
of the parental strain HN878 was also resequenced, and differ-
ences shared among all the rabbit samples and the laboratory 
parental strain were also filtered out.
Determination of caseum pH
About 30 min after euthanasia, the pH of pulmonary TB lesion 
caseum was determined by using different pH indicator strips 
(Table S1). Caseum was aseptically removed from incised lesions 
and applied as a thin layer on the indicator section of a pH strip 
that was prewetted with molecular-grade water (Life Technol-
ogies). The pH was read after 30 s of incubation. Surgical in-
struments were rinsed with molecular-grade water and dried 
between measurements. Up to three measurements of individual 
lesions were taken.
Statistical analyses
This study included a total of 54 rabbits and 1,380 lesions. To de-
tect statistically significant differences in CEQs, CFUs, or CEQs/
CFUs per lesion, groups were compared by using a two-tailed 
Mann-Whitney U (nonparametric) test, which is adequate for 
analyzing nonnormally distributed (particularly “zero-inflated” 
in the case of CFU) datasets (GraphPad Prism 7). Proportions 
shown in Fig. 4 D were analyzed by using Fisher's exact test (two-
sided for comparisons of treated versus untreated group pairs). 
In CEQ/CFU ratio analyses shown in Figs. 1, 5, and S2, lesions that 
harbored undetectable CEQs (the majority of which had no de-
tectable CFUs) were excluded rather than set to zero because the 
limit of CEQ detection was ∼100 (Fig. S3). P values <0.05 were 
considered statistically significant. *, P < 0.05; **, P < 0.01; ***, 
P < 0.001; ****, P < 0.0001. All data are presented as median ± 
95% confidence interval (CI), except for data shown as mean and 
standard deviation in Fig. S3 (C and D).
Online supplemental material
Fig. S1 shows the characterization of lesion weight as a function 
of disease progression and bacterial burden; the bacterial bur-
den normalized to tissue weight as a function of tissue and le-
sion type, the evolution of cumulative burden (CEQ) as disease 
progresses, and the relationship between bacterial burden and 
cumulative burden as disease progresses in cellular and necrotic 
lesions. Data shown in Fig. S1 are from drug-naive rabbits only. 
Fig. S2 shows histopathological evidence supporting release 
of cavity material into airways and the association of bacteria 
with neutrophils. Fig. S3. summarizes methodological consid-
erations, validation, and calibration of the CEQ analyses. Table 
S1 summarizes pH measurements made in necrotic lesions and 
caseum from rabbits with active TB. Table S2 outlines the genetic 
polymorphisms of Mtb bacilli retrieved from rabbit lesions 20 
wk postinfection. Table S3 describes the dose projection scenar-
ios considered to reproduce human exposure of PZA in rabbits. 
Table S4 shows the PZA and POA PK parameters achieved in rab-
bits on treatment. Dataset S1 contains the complete CFU and CEQ 
data generated and analyzed in this work.
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